Robert Li, PhD has served as our Chief Executive Officer since April 2020. Dr. Li is a seasoned drug developer with over 15 years of biopharmaceutical experience in translational research and leadership with cross functional teams to support IND, NDA/BLA, and global regulatory interactions during the drug discovery and development of both small and large molecules.  Prior to LintonPharm, Dr. Li held multiple leadership roles such as immunology therapeutic area lead and cross functional team lead in global pharmaceutical companies such as Bristol-Myers Squibb, Genentech, and Vir Biotechnology etc. Dr. Li’s expertise especially in therapeutic areas of oncology, immunology, and cancer immunology (e.g., immune checkpoints, T cell engager, NK cell engager) has been well recognized in industry. He is frequently invited as speaker, chair, and/or panelist for numerous impactful global conferences such as AACR-FDA workshops, BioSafe annual meetings, and Bispecific summits etc.